Micron Biomedical
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| infectiousDisease | ×0.70 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×0.70 | 3 |
Strategy profile
Based on 4 disclosed transactions, Micron Biomedical concentrates its licensing activity in InfectiousDisease. Micron Biomedical pays a 0.70x discount to market median, with the strongest premiums in InfectiousDisease (0.70x). Their most common deal structure is Co Development, with an average disclosed value of $2M. Most recent activity: 2025.
Premium by therapeutic area
How Micron Biomedical pays relative to peer medians in each TA
Pipeline coverage & gaps
Micron Biomedical has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| Co DevelopmentPrimary | 2 | $2M | $2M |
| CollaborationPrimary | 2 | $2M | $2M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | needle-free mRNA influenza vaccines | HHS/BARDA | influenza | unknown | $2M | $2M |
| 2025 | needle-free mRNA influenza vaccines | BARDA | influenza | preclinical | $2M | $2M |
| 2025 | mRNA influenza vaccines | Zipcode Bio | influenza | preclinical | $2M | $2M |
| 2025 | needle-free mRNA avian/seasonal flu vaccines | HHS | avian/seasonal influenza | preclinical | $2M | $2M |
How this is computed
For each Micron Biomedical deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.003, clamped to [0.7, 1.5].